Building the leading CRISPR platform for unmet needs together

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, our company’s ultracompact systems are designed to be more specific and enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, reverse transcriptase editing, and epigenetic editing.

Our company is building out its wholly owned pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of our innovative and proprietary technology platform. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further our mission to transform the lives of patients and deliver on the promise of CRISPR technologies.

We have pioneered a novel approach to discovering and engineering Cas proteins and novel CRISPR technologies. Our CRISPR platform technologies can be used across many industries such as healthcare, agriculture, environmental monitoring, and more.

Mammoth is committed to advancing science internally and through collaborations in the service of its mission to discover, develop and commercialize drugs to improve the lives of patients. Please get in touch with us below if you would like to join us on our journey.